Dr. Alvin Luk

Title: A Confirmatory Phase 3 Clinical Trial of Rituximab Biosimilar HLX01 Compared with Reference Rituximab in Diffuse Large B-Cell Lymphoma


Dr. Alvin Luk, Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech Inc., holds an MBA from Harvard Business School, earned his doctoral degree in Neuroscience from the University of California San Francisco Medical School (UCSF) and is certified for clinical research from the Association of Clinical Research Professionals. Previously,Dr. Luk has held executive positions at companies such as Spark, Biogen, BayerAG, Avigen (Sanofi) and Tularik (Amgen). He has over 26 years of global drug development, strategic management and clinical medical leadership experience. During 2006-2009, Dr. Luk was a member of the USA FDA Clinical Design Committee focusing on adaptive clinical trial designs to shorten drug development timeline. 

Research Interest

Oncological diseases, Biologics and Regenerative medicines

No Content found...